The influence of FCGR2A and FCGR3A polymorphisms on the survival of patients with recurrent or metastatic squamous cell head and neck cancer treated with cetuximab

The influence of FCGR2A and FCGR3A polymorphisms on the survival of patients with recurrent or metastatic squamous cell head and neck cancer treated with cetuximabThe Pharmacogenomics Journal, Published online: 18 July 2017; doi:10.1038/tpj.2017.37

https://www.nature.com/articles/tpj201737

Source: The Pharmacogenomics Journal - July 18, 2017 Category: Drugs & Pharmacology Authors: T Magnes T Melchardt C Hufnagl L Weiss C Mittermair D Neureiter E Klieser G Rinnerthaler S Roesch A Gaggl R Greil A Egle Source Type: research

More News: Cancer | Cancer & Oncology | Erbitux | Head and Neck Cancer | Squamous Cell Carcinoma